Mary-Ellen Taplin
Professor of Medicine at Harvard Medical School
Biography
Harvard Medical School
Dr. Taplin received her MD in 1986 from the University of Massachusetts, Worcester. She completed a residency in internal medicine and chief residency at the University of Massachusetts Medical Center and an oncology-hematology fellowship at Beth Israel Hospital and Harvard Medical School. Dr. Taplin was on staff in medical oncology-hematology as an assistant and then associate professor of medicine at the University of Massachusetts from 1993 to 2003, when she joined Dana-Farber Cancer Institute.
Clinical Interests
- Bladder cancer
- Clinical trials
- Hormone and chemotherapy
- Kidney cancer
- Prostate cancer
- Testis cancer
Videos
Biologic rationale for next-generation AR inhibitors - Mary-Ellen Taplin
Dana-Farber Cancer Institute: Mary-Ellen Taplin, MD (ASCO GU21 prostate cancer)
Helping patients make the best choice for them: Dr. Mary-Ellen Taplin | Dana-Farber Cancer Institute
Dr. Mary-Ellen Taplin on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer
Dr. Mary-Ellen Taplin on Treating Prostate/GU Cancers | Dana-Farber Cancer Institute
Dr. Mary-Ellen Taplin on Dual Pathway Inhibition in Prostate Cancer
Dr. Taplin on ARMOR3-SV Trial for Patients with mCRPC
Key considerations for the VISION trial of LuPSMA in mCRPC | Mary-Ellen Taplin
Dr. Mary-Ellen Taplin on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate
Dr. Mary-Ellen Taplin on Abiraterone Acetate's Mechanism of Action
Dr. Mary-Ellen Taplin on the Mechanism of Action of Enzalutamide (MDV3100)
Read about executive education
Other experts
Looking for an expert?
Contact us and we'll find the best option for you.